BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 18555675)

  • 1. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.
    Pulkkinen M; Pikkarainen J; Wirth T; Tarvainen T; Haapa-aho V; Korhonen H; Seppälä J; Järvinen K
    Eur J Pharm Biopharm; 2008 Sep; 70(1):66-74. PubMed ID: 18555675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
    Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
    Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
    Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
    J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel nanoparticles for the potential treatment of brain tumors.
    Koziara JM; Lockman PR; Allen DD; Mumper RJ
    J Control Release; 2004 Sep; 99(2):259-69. PubMed ID: 15380635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of MPEG-PLA nanoparticle for honokiol delivery in vitro.
    Zheng X; Kan B; Gou M; Fu S; Zhang J; Men K; Chen L; Luo F; Zhao Y; Zhao X; Wei Y; Qian Z
    Int J Pharm; 2010 Feb; 386(1-2):262-7. PubMed ID: 19932160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graphene oxide stabilized by PLA-PEG copolymers for the controlled delivery of paclitaxel.
    Angelopoulou A; Voulgari E; Diamanti EK; Gournis D; Avgoustakis K
    Eur J Pharm Biopharm; 2015 Jun; 93():18-26. PubMed ID: 25817600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
    Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
    Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
    Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
    J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro targeting of avidin-expressing glioma cells with biotinylated persistent luminescence nanoparticles.
    Maldiney T; Kaikkonen MU; Seguin J; le Masne de Chermont Q; Bessodes M; Airenne KJ; Ylä-Herttuala S; Scherman D; Richard C
    Bioconjug Chem; 2012 Mar; 23(3):472-8. PubMed ID: 22250884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-loaded polymeric nanoparticles based on PCL-PEG-PCL: preparation, in vitro and in vivo evaluation.
    Zhang L; He Y; Yu M; Song C
    J Control Release; 2011 Nov; 152 Suppl 1():e114-6. PubMed ID: 22195789
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
    Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
    Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
    Chavanpatil MD; Patil Y; Panyam J
    Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and in vitro properties of redox-responsive polymeric nanoparticles for paclitaxel delivery.
    Song N; Liu W; Tu Q; Liu R; Zhang Y; Wang J
    Colloids Surf B Biointerfaces; 2011 Oct; 87(2):454-63. PubMed ID: 21719259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
    Patil Y; Sadhukha T; Ma L; Panyam J
    J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
    Danhier F; Ucakar B; Magotteaux N; Brewster ME; Préat V
    Int J Pharm; 2010 Jun; 392(1-2):20-8. PubMed ID: 20226846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles.
    Zhang Z; Feng SS
    Biomaterials; 2006 Jul; 27(21):4025-33. PubMed ID: 16564085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells.
    Hu Y; Xie J; Tong YW; Wang CH
    J Control Release; 2007 Mar; 118(1):7-17. PubMed ID: 17241684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma.
    Xin H; Jiang X; Gu J; Sha X; Chen L; Law K; Chen Y; Wang X; Jiang Y; Fang X
    Biomaterials; 2011 Jun; 32(18):4293-305. PubMed ID: 21427009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors.
    Luo G; Yu X; Jin C; Yang F; Fu D; Long J; Xu J; Zhan C; Lu W
    Int J Pharm; 2010 Jan; 385(1-2):150-6. PubMed ID: 19825404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active targeting behaviors of biotinylated pluronic/poly(lactic acid) nanoparticles in vitro through three-step biotin-avidin interaction.
    Xiong XY; Gong YC; Li ZL; Li YP; Guo L
    J Biomater Sci Polym Ed; 2011; 22(12):1607-19. PubMed ID: 20699057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.